{"id":4655,"date":"2025-07-14T11:28:06","date_gmt":"2025-07-14T02:28:06","guid":{"rendered":"https:\/\/bionauts.jp\/?p=4655"},"modified":"2025-07-15T15:50:22","modified_gmt":"2025-07-15T06:50:22","slug":"c11orf97-a-novel-cancer-specific-target-inducing-apoptosis","status":"publish","type":"post","link":"https:\/\/bionauts.jp\/?p=4655","title":{"rendered":"C11orf97: A Novel Cancer-Specific Target Inducing Apoptosis"},"content":{"rendered":"<h3>Advantage and Core Benefit<\/h3>\n<ul>\n<li>Tumor-Selective Cell Death Induction: C11orf97 was identified as a binding partner of ferrichrome, an antitumor peptide that selectively induces cell death in cancer cells. It holds strong potential as a cancer-specific therapeutic target.<\/li>\n<li>Low Toxicity and High Selectivity: Ferrichrome shows no toxicity even at high doses, and no significant abnormalities have been reported in C11orf97 knockout mice, indicating C11orf97 is a highly selective and safe therapeutic target.<\/li>\n<li>siRNA-Mediated Antitumor Effect: Knockdown of C11orf97 via siRNA has demonstrated significant tumor suppression in vitro and in mouse xenograft models.<\/li>\n<\/ul>\n<h3>Background and Technology<\/h3>\n<p>Ferrichrome is a bacterial siderophore (metal-chelating compound) that selectively induces cell death in colorectal, gastric, pancreatic, and esophageal cancer cells. Preclinical toxicity studies in mice have shown that repeated administration at four times the therapeutic dose for two weeks, or a single administration at 60 times the dose, caused no toxicity. Normal cells were also unaffected, suggesting that ferrichrome and its molecular target may offer a low-toxicity cancer treatment strategy.<br \/>\nTo identify the target of ferrichrome, a CRISPR library screening was conducted, leading to the discovery of C11orf97, a previously uncharacterized gene. Direct binding between ferrichrome and C11orf97 protein was confirmed. Furthermore, siRNA-mediated knockdown of C11orf97 significantly suppressed the growth of various cancer cell lines without affecting normal cells. In mouse xenograft models, siRNA targeting C11orf97 showed clear tumor-suppressive effects.<br \/>\nThese results highlight C11orf97 as a core mediator of ferrichrome\u2019s antitumor activity and a promising cancer-specific target with high selectivity and safety. It has broad potential for drug development across various modalities, including nucleic acid therapeutics, small molecules, and PROTACs.<\/p>\n<h3>Data<\/h3>\n<ul>\n<li>CRISPR Screening: C11orf97 was identified through a CRISPR library screen as a key mediator of ferrichrome\u2019s antitumor effect.<\/li>\n<li>siRNA-Based Antitumor Effect: siRNA targeting C11orf97 demonstrated significant tumor volume reduction in a mouse xenograft model (see figure).<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse; width: 100%;\">\n<tbody>\n<tr>\n<td style=\"width: 100%;\"><a href=\"http:\/\/bionauts.jp\/wp-content\/uploads\/2025\/07\/WL-05281.png\"><img decoding=\"async\" loading=\"lazy\" class=\"alignleft size-full wp-image-4656\" src=\"http:\/\/bionauts.jp\/wp-content\/uploads\/2025\/07\/WL-05281.png\" alt=\"\" width=\"574\" height=\"340\" srcset=\"https:\/\/bionauts.jp\/wp-content\/uploads\/2025\/07\/WL-05281.png 574w, https:\/\/bionauts.jp\/wp-content\/uploads\/2025\/07\/WL-05281-300x178.png 300w\" sizes=\"(max-width: 574px) 85vw, 574px\" \/><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Patent &amp; Publication<\/h3>\n<p>Patent pending (C11orf97-related; unpublished), JP Patent No. 6830255 (Ferrichrome; granted)<br \/>\nPublications: Konishi H, Nat Commun. 2016; Kita A, Int J Oncol. 2020<\/p>\n<h3>Researcher<\/h3>\n<p>Dr. Hiroaki Konishi (Asahikawa Medical University)<\/p>\n<h3>Expectations<\/h3>\n<p>We welcome collaborative research and licensing opportunities with pharmaceutical and biotech companies interested in developing nucleic acid therapeutics, PROTACs, or other novel modalities targeting C11orf97. Unpublished data can be disclosed under a confidentiality agreement with Asahikawa Medical University. Direct meetings with the lead researcher can also be arranged upon request.<\/p>\n<p>&nbsp;<\/p>\n<p>Project ID:WL-05281<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Development of Molecular Targeted and Nucleic Acid Therapeutics for C11orf97<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[1],"tags":[],"categories_of_inventions":[46],"disease_categories___indication":[],"asset_type":[],"development_phase":[],"medicine":[102,105,97,103,108,121,112,96],"other_than_medicine":[],"material":[],"engineering":[],"software_it":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/4655"}],"collection":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4655"}],"version-history":[{"count":1,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/4655\/revisions"}],"predecessor-version":[{"id":4657,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/4655\/revisions\/4657"}],"wp:attachment":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4655"},{"taxonomy":"categories_of_inventions","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories_of_inventions&post=4655"},{"taxonomy":"disease_categories___indication","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fdisease_categories___indication&post=4655"},{"taxonomy":"asset_type","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fasset_type&post=4655"},{"taxonomy":"development_phase","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fdevelopment_phase&post=4655"},{"taxonomy":"medicine","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedicine&post=4655"},{"taxonomy":"other_than_medicine","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fother_than_medicine&post=4655"},{"taxonomy":"material","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmaterial&post=4655"},{"taxonomy":"engineering","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fengineering&post=4655"},{"taxonomy":"software_it","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fsoftware_it&post=4655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}